Pain Management Of The Terminally Ill

Better Pain Management Is Essential for Reducing Addiction to Prescription Painkillers

But the reality is that no one should have to make the awful choice between intolerable pain and suicide. We are not awaiting some scientific breakthrough with which to conquer pain. There is already available a vast array of means to help patients live free of pain. Advances in pain management in recent years include new drugs, self-administered morphine pumps, epidural catheters, biofeedback, adaptive devices, and even clinics established specifically to treat pain. In spite of the many benefits of good pain relief – such as patient well-being, medical cost savings, and less lost time from work – and in spite of the modern arsenal of weapons against pain, many patients live their last weeks and months in severe discomfort or pain. This can – and must – be changed! One positive outcome of the discussion about physician-assisted suicide is that doctors, nurses, and the public are learning more about proper assessment and treatment of pain. Good pain management is a reality, but it requires dedication and time. Patients in pain and their families should insist that every effort be made to control pain, including consulatation with a hospice physician/pharmacist or a referral to a pain management clinic if necessary. If a physician does not have the knowledge, compassion or time necessary to assess and treat pain effectively, the patient should seek another doctor! Researchers studying American cancer patients discovered that those who were actually in pain were more likely to reject the notion of physician-assisted suicide and euthanasia than those who anticipate or fear pain. Researchers concluded that patients who are actually confronting the problem are more interested in getting rid of their pain than in dying (Lancet, 6/29/96:1805-1810).
For the original version including any supplementary images or video, visit

Endo builds pain management business

Endo Pharma

Dr. Galer received his medical doctorate and a neurology residency from Albert Einstein in New York and two Pain Fellowships, at Memorial Sloane-Kettering in New York and University of California San Francisco, as well as headache training at Montefiore Headache Clinic in New York and University of California San Francisco. — Arnold R. Gammaitoni, Pharm.D., Vice President, Medical and Scientific Affairs — Prior to joining Zogenix, Dr. Gammaitoni served as Vice President of Scientific Affairs of the Pain Group at Nuvo Research. Prior to joining Nuvo, Dr. Gammaitoni was Global Director of Scientific Affairs for Analgesia, Immunology, and Anesthesia at Merck & Co. Previous to Merck, he served as Senior Director of Medical Affairs at Endo Pharmaceuticals. Dr Gammaitoni has also been a clinical practitioner with a focus on pain management and has authored or co-authored over 50 articles. He received his doctoral degree in pharmacy from the Philadelphia College of Pharmacy. — Marsha R.
For the original version including any supplementary images or video, visit

Physician registration required for practice of pain management

Pain Management Registration Required. Beginning January 1, 2014, and continuing every year thereafter, all physicians who provide pain management services (as defined by the Board) must obtain a pain management registration from the Board.The deadline for initial registration for 2014 is February 15, 2014. In subsequent years, renewal will occur during the same period as medical license renewals (October through December), and annual registrations will expire December 31 of each year. Pain Management Services Defined. Pain management services are those medical services that involve the prescription of controlled substances in order to treat chronic non-malignant pain by a physician who treats pain. The Board defines the provision of pain management services as: A physician practice which advertises or holds itself out to the public as a provider of pain management services; OR A physician practice which dispenses opioids; OR A physician practice with greater massage therapy north york than 50% being provided pain management; OR A physician practice in which any of the providers of pain management services are rated in the top 10% of practitioners who prescribe controlled substances in Alabama, as determined by the Alabama Prescription Drug Monitoring Database on an annual basis. Requirements for the Provision of Pain Management Services. In addition to annual registration, the Board’s standards for Pain Management Services also require the following: Pain Management Services must be provided at alocation owned and operated by 1) one or more physicians licensed in Alabama; 2) a business entity registered with the Alabama Secretary ofState; or 3) a government entity or body, or political subdivision,including state universities and schools. Each Pain Management practice must be under the direction of a medical director who is a physician with a current,unrestricted Alabama medical license. Each medical director must meet certain training and on siterequirements. Every registrant is required to register with theAlabama Department of Public Health’s Prescription Drug MonitoringProgram. In addition, the Board specifies certain requirements and guidelines for physicians using controlled substances for the treatment of pain. Information Required for Registration. The Board requires the following information for pain management services registration: A completed application
For the original version including any supplementary images or video, visit

Zogenix Appoints Chief Medical Officer and Expands Medical Leadership Team

The move expands Endo’s existing pain management business and brings NuPathe’s lead product, the migraine treatment Zecuity, into the fold. As part of the agreement, NuPathe is also eligible to receive additional cash payments if Endo meets sales targets for Zecuity, which is a single-use patch version of the painkiller sumatriptan the active ingredient in GlaxoSmithKline’s Imitrex. NuPathe has previously announced its intention to seek a partnership to maximise the commercial potential of Zecuity, which became the first approved prescription migraine patch in the US at the beginning of the year. As such, NuPathe has delayed launching Zecuity in the US, sating the timing of the launch of Zecuity will be dependent upon the completion of a commercial partnership for Zecuity and/or obtaining the additional capital required for launch. They now have such a partner in Endo, which has experience in pain management via products such as Frova (frovatriptan succinate), Zydone (hydrocodone bitartrate/acetaminophen) and the Opana (oxymorphone hydrochloride) franchise of products. Endo also has an existing pain patch in the form of Lidoderm, which contains the active ingredient lidocaine. Rajiv De Silva, president and CEO of Endo, confirmed that the company intends to launch Zecuity in the first half of 2014. The company will do this by leveraging [its] existing commercial expertise in pain and migraine management and the current infrastructure of our branded pharmaceuticals business overall, said De Silva. NuPathe’s CEO Armando Anido said: We believe this acquisition by Endo will increase the potential for Zecuity to make a meaningful difference for patients we have worked so hard to serve.” Article by
For the original version including any supplementary images or video, visit

She hoped that this pain clinic would provide an alternative to opiates. Then she would go into rehab, she said. I marveled that she still had hope. Yes, it is true that some people take prescription painkillers to get high, but a great many people who become addicted are just trying to live with pain. Modern medicine has a long way to go to help them. The problem of pain has not gone unnoticed, of course. In fact, the Affordable Care Act (a.k.a. Obamacare) required the Institute of Medicine to do a study about pain and its treatment. The results were reported in 2011 and were quite startling. (5) More than 100 million Americans suffer from “chronic” pain, according to the report. That’s one in three Americans.
For the original version including any supplementary images or video, visit


Leave a Reply

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out /  Change )

Google+ photo

You are commenting using your Google+ account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )


Connecting to %s